Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.54 |
| ▸ | LMNA | P02545 | 5/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | PHGDH | O43175 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2388044 | 0.92 | ALDH1A1 (0.52) | ALDH1A1LMNASMN1; SMN2MAPTGAA | |
| Nucleozin SCHEMBL29360670 | 0.92 | NPC1 (0.61) | ALDH1A1LMNASMN1; SMN2MAPTGAA | |
| Nucleozin SCHEMBL1225006 | 0.92 | NPC1 (0.61) | ALDH1A1LMNASMN1; SMN2MAPTGAA | |
| SCHEMBL12312892 | 0.88 | ALDH1A1 (0.51) | ALDH1A1LMNASMN1; SMN2MAPTGAA | |
| SCHEMBL16086860 | 0.87 | ALDH1A1 (0.48) | ALDH1A1LMNASMN1; SMN2MAPTGAA | |
| SCHEMBL12263824 | 0.87 | ALDH1A1 (0.47) | ALDH1A1LMNASMN1; SMN2MAPTGAA | |
| SCHEMBL10082093 | 0.86 | LMNA (0.57) | ALDH1A1LMNASMN1; SMN2MAPTMEN1 | |
| SCHEMBL899570 | 0.85 | LMNA (0.67) | ALDH1A1LMNASMN1; SMN2MAPTGAA | |
| SCHEMBL12691832 | 0.84 | NPC1 (0.63) | ALDH1A1LMNASMN1; SMN2GAAKMT2A | |
| SCHEMBL898748 | 0.84 | LMNA (0.57) | ALDH1A1LMNASMN1; SMN2MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9212177-B2 | Antiviral compounds and methods of making and using thereof | VERSITECH LIMITED (HK) | 2015-12-15 | — | — | US | claimed |
| EP-2462138-B1 | ANTIVIRAL COMPOUNDS AND METHODS OF MAKING | VERSITECH LTD (CN) | 2014-09-24 | — | — | EP | claimed |
| US-20120149715-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | VERSITECH LIMITED (HK) | 2012-06-14 | — | — | US | claimed |
| WO-2011147199-A1 | COMPOUNDS AND METHODS FOR TREATING VIRAL INFECTIONS | VERSITECH LIMITED (CN) | 2011-12-01 | — | — | WO | claimed |
| US-20110212975-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF MAKING AND USING THEREOF | THE UNIVERSITY OF HONG KONG | 2011-09-01 | — | — | US | claimed |
| US-9212177-B2 | Antiviral compounds and methods of making and using thereof | VERSITECH LIMITED (HK) | 2015-12-15 | — | — | US | disclosed |
| US-9212177-B2 | Antiviral compounds and methods of making and using thereof | VERSITECH LIMITED (HK) | 2015-12-15 | — | — | US | disclosed |
| US-9212177-B2 | Antiviral compounds and methods of making and using thereof | VERSITECH LIMITED (HK) | 2015-12-15 | — | — | US | disclosed |
| EP-2462138-B1 | ANTIVIRAL COMPOUNDS AND METHODS OF MAKING | VERSITECH LTD (CN) | 2014-09-24 | — | — | EP | disclosed |
| US-20130325429-A1 | Compounds and Methods for the Treatment of Viral Infections | THE UNIVERSITY OF HONG KONG | 2013-12-05 | — | — | US | disclosed |
| US-20120149715-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | VERSITECH LIMITED (HK) | 2012-06-14 | — | — | US | disclosed |
| EP-2462138-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF MAKING AND USING THERE OF CROSS REFERENCE TO RELATED APPLICATIONS | Versitech Limited (CN) | 2012-06-13 | — | — | EP | disclosed |
| WO-2011147198-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF PROLIFERATIVE DISEASES | VERSITECH LIMITED (CN) | 2011-12-01 | — | — | WO | disclosed |
| US-20110212975-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF MAKING AND USING THEREOF | THE UNIVERSITY OF HONG KONG | 2011-09-01 | — | — | US | disclosed |
| US-20110212975-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF MAKING AND USING THEREOF | THE UNIVERSITY OF HONG KONG | 2011-09-01 | — | — | US | disclosed |
| US-20110212975-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF MAKING AND USING THEREOF | THE UNIVERSITY OF HONG KONG | 2011-09-01 | — | — | US | disclosed |
| WO-2011015037-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF MAKING AND USING THERE OF CROSS REFERENCE TO RELATED APPLICATIONS | THE UNIVERSITY OF HONGKONG (CN) | 2011-02-10 | — | — | WO | disclosed |
| WO-2011015037-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF MAKING AND USING THERE OF CROSS REFERENCE TO RELATED APPLICATIONS | THE UNIVERSITY OF HONGKONG (CN) | 2011-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149715-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | HAVCR2, SNRPE, HDLBP | ALDH1A1 4452/4885LMNA 1799/4885SMN1; SMN2 4050/4885 |
| US-20110212975-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF MAKING AND USING THEREOF | VIP, H1-3, MAVS | ALDH1A1 2085/4885LMNA 412/4885SMN1; SMN2 523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.